IMNN

ImunonB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.20

+74.9% vs current

Most likely

Base case

45%

Probability

Target price

$1.90

+3.8% vs current

B-

Bear case

30%

Probability

Target price

$1.00

-45.4% vs current

AI sentiment snapshot

Latest data as of 2026-06-24

AI commentary

Deterministic scoring stays modestly positive, helped by Phase 2 survival commentary, FDA-aligned Phase 3 protocol language, ahead-of-plan enrollment commentary, and the recent financing headline. Still, this remains a low-coverage, micro-cap biotech monitoring name where financing mechanics can outweigh operating progress in the near term; there is no strong analyst-revision, social-coverage, options, or short-interest evidence in the packet to justify a higher-conviction rerating [#SEC-8K-2026-05-12].

RankAlpha Sentiment Codex - 2026-06-24

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-09-30eventOVATION 3 enrollment updates are the main operating proof pointHigh impact

Management said Phase 3 OVATION 3 enrollment continues ahead of plan, and the company also said FDA has reviewed and aligned with the Phase 3 protocol and path to BLA filing; a concrete enrollment, site, or execution update would be the clearest intermediate validation signal before any major registrational data event [#SEC-8K-2026-05-12].

2026-09-30catalystRunway and financing terms remain the main near-term stock driverHigh impact

Recent news indicates Imunon secured a $10 million funding package to advance the Phase 3 ovarian cancer study, while the company's May 2026 earnings exhibit reported a Q1 2026 net loss of $4.3 million and a strategic reorganization intended to reduce operating expenses while supporting OVATION 3; for a micro-cap biotech funding a long pivotal program, future capital terms and cash runway remain likely to dominate near-term trading [#SEC-8K-2026-05-12].

2029-03-31catalystPhase 2 survival signal still needs successful Phase 3 confirmationHigh impact

The core upside case remains that IMNN-001's Phase 2 ovarian cancer survival signal can translate into registrational success: the company reported a final 14.7-month median overall-survival increase in OVATION 2 and said Phase 3 enrollment is expected to complete by Q1 2029, leaving a long and execution-dependent rerating path despite encouraging Phase 2 data [#SEC-8K-2026-05-12][#SEC-8K-2026-03-31].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-24 • Updated nightlySource: Internal modelMethodology